BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37265703)

  • 1. Refractory hypercalcemia of malignancy: a problem with many potential roots.
    Farooki A
    Front Endocrinol (Lausanne); 2023; 14():1088984. PubMed ID: 37265703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology and management of severe hypercalcemia.
    Nussbaum SR
    Endocrinol Metab Clin North Am; 1993 Jun; 22(2):343-62. PubMed ID: 8325291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
    Van den Eynden GG; Neyret A; Fumey G; Rizk-Rabin M; Vermeulen PB; Bouizar Z; Body JJ; Dirix LY
    Bone; 2007 Apr; 40(4):1166-71. PubMed ID: 17188588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercalcemia of Malignancy.
    Hu MI
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):721-728. PubMed ID: 34774243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Hypercalcemia of Malignancy.
    Chakhtoura M; El-Hajj Fuleihan G
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
    El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
    J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hypercalcaemia of malignancy in adults.
    Mc Donald D; Drake MT; Crowley RK
    Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.
    Chukir T; Liu Y; Hoffman K; Bilezikian JP; Farooki A
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1115-23. PubMed ID: 31841590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-related hypercalcemia and potential treatments.
    Almuradova E; Cicin I
    Front Endocrinol (Lausanne); 2023; 14():1039490. PubMed ID: 37033238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of malignancy-associated hypercalcemia].
    Endo I; Inoue D
    Clin Calcium; 2006 Apr; 16(4):665-69. PubMed ID: 16582519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercalcemia of malignancy and new treatment options.
    Sternlicht H; Glezerman IG
    Ther Clin Risk Manag; 2015; 11():1779-88. PubMed ID: 26675713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypercalcemia of malignancy in the palliative care patient: a treatment strategy.
    Kovacs CS; MacDonald SM; Chik CL; Bruera E
    J Pain Symptom Manage; 1995 Apr; 10(3):224-32. PubMed ID: 7543127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of hypercalcemia of malignancy.
    Solimando DA
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S4-7. PubMed ID: 11757205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab: a new agent in the management of hypercalcemia of malignancy.
    Thosani S; Hu MI
    Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypercalcemia of malignancy--new insights into an old syndrome.
    Esbrit P
    Clin Lab; 2001; 47(1-2):67-71. PubMed ID: 11214225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
    Rosner MH; Dalkin AC
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Refractory hypercalcemia in patient with lung cancer].
    Grzywacz A; Dziuk M; Niemczyk S
    Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.